STING-CASM-GABARAP-LRRK2 Pathway in Parkinson's Disease

STING-CASM-GABARAP-LRRK2 Pathway in Parkinson's Disease

Overview

The STING-CASM-GABARAP-LRRK2 pathway represents a novel mechanistic link between innate immune activation and [LRRK2](/genes/lrrk2) kinase dysfunction in [Parkinson's disease](/diseases/parkinsons-disease)[@qiu2024]. This pathway reveals how lysosomal damage, microbial infection, and cellular stress converge to activate LRRK2, providing a unifying mechanism for various environmental triggers implicated in PD pathogenesis.

This mechanism is significant because [LRRK2](/genes/lrrk2) mutations that increase kinase activity are among the most common genetic risk factors for familial and sporadic [Parkinson's disease](/diseases/parkinsons-disease)[@cookson2022]. Understanding the upstream activators of LRRK2 provides opportunities for therapeutic intervention at the earliest stages of pathogenesis.

Historical Context and Discovery

The pathway was recently elucidated through research published in 2024 (PMID:39812709), integrating findings from multiple fields:

• 2012-2018: Discovery of CASM (conjugation of ATG8 to single membranes) as a non-canonical autophagy process
• 2020-2022: Identification of GABARAP family proteins as key players in LRRK2 recruitment
• 2024: Demonstration that STING activation triggers CASM, leading to LRRK2 activation via GABARAP

STING-CASM-GABARAP-LRRK2 Pathway in Parkinson's Disease

Overview

The STING-CASM-GABARAP-LRRK2 pathway represents a novel mechanistic link between innate immune activation and [LRRK2](/genes/lrrk2) kinase dysfunction in [Parkinson's disease](/diseases/parkinsons-disease)[@qiu2024]. This pathway reveals how lysosomal damage, microbial infection, and cellular stress converge to activate LRRK2, providing a unifying mechanism for various environmental triggers implicated in PD pathogenesis.

This mechanism is significant because [LRRK2](/genes/lrrk2) mutations that increase kinase activity are among the most common genetic risk factors for familial and sporadic [Parkinson's disease](/diseases/parkinsons-disease)[@cookson2022]. Understanding the upstream activators of LRRK2 provides opportunities for therapeutic intervention at the earliest stages of pathogenesis.

Historical Context and Discovery

The pathway was recently elucidated through research published in 2024 (PMID:39812709), integrating findings from multiple fields:

• 2012-2018: Discovery of CASM (conjugation of ATG8 to single membranes) as a non-canonical autophagy process
• 2020-2022: Identification of GABARAP family proteins as key players in LRRK2 recruitment
• 2024: Demonstration that STING activation triggers CASM, leading to LRRK2 activation via GABARAP

Molecular Mechanism

Step 1: STING Activation

[STING](/mechanisms/cgas-sting-neurodegeneration) (Stimulator of Interferon Genes) is activated by multiple stimuli[@qiu2024]:

Direct STING agonists:

• DMXAA: A small molecule STING agonist
• cGAMP: The second messenger produced by [cGAS](/mechanisms/cgas-sting-neurodegeneration)

• LLOME (L-leucyl-L-leucine methyl ester): Lysosomal damage
• ML SA1: Lysosomal membrane permeabilization
• Nigericin: Ionophore causing lysosomal stress

Step 2: CASM Induction

Upon STING activation, the conjugation of ATG8 to single membranes (CASM) pathway is triggered[@qiu2024]:

Key components:

• ATG16L1: Essential for LC3/GABARAP lipidation on single membranes
• ATG12-ATG5 conjugate: Required for ATG8 family protein lipidation
• ATG3: E2-like enzyme facilitating conjugation

Step 3: GABARAP Recruitment of LRRK2

The critical discovery is that GABARAP specifically mediates LRRK2 recruitment and activation[@qiu2024]:

LIR (LC3-Interacting Region) motifs:

• Two predicted LIR motifs in LRRK2
• Direct interaction between GABARAP and LRRK2
• Other ATG8 family members cannot substitute for GABARAP

Pathway Validation

The requirement for CASM and GABARAP has been experimentally validated[@qiu2024]:

| Requirement | Evidence |
|-------------|----------|
| CASM required | Blocked by ATG16L1 deletion |
| CASM required | Blocked by Salip (ATG7 inhibitor) |
| CASM required | Blocked by SopF (ATG4B inhibitor) |
| GABARAP required | Other ATG8 members cannot substitute |
| TBK1/IKKε not required | Kinase inhibitors do not block pathway |

Stimuli Converging on CASM-LRRK2 Activation

The pathway provides a mechanistic explanation for how diverse stressors activate [LRRK2](/genes/lrrk2):

Cellular Stressors Linking to LRRK2

Lysosomal dysfunction:

• Lysosomal membrane permeabilization triggers CASM
• Relevant to [Parkinson's disease](/diseases/parkinsons-disease) where lysosomal dysfunction is prominent
• [GBA](/genes/gba) mutations cause lysosomal dysfunction and increase [PD risk](/diseases/parkinsons-disease)

• Mitochondrial DNA release activates [cGAS-STING](/mechanisms/cgas-sting-neurodegeneration)
• Common in [Parkinson's disease](/diseases/parkinsons-disease) substantia nigra
• Links mitochondrial genetics ([PINK1](/genes/pink1), [PARK2](/genes/parkin)) to LRRK2 activation

• Pathogen-associated molecular patterns activate STING
• Potential link to [gut-brain axis](/mechanisms/gut-brain-axis-neurodegeneration) in PD

Disease Relevance

Parkinson's Disease

The pathway is highly relevant to [Parkinson's disease](/diseases/parkinsons-disease) pathogenesis[@qiu2024][@cookson2022]:

Genetic risk:

• [LRRK2](/genes/lrrk2) G2019S mutation increases kinase activity
• Common in familial and sporadic PD
• The pathway explains how environmental factors may trigger LRRK2 activation in non-carriers

• Lysosomal dysfunction is a hallmark of PD
• Mitochondrial dysfunction in substantia nigra
• Chronic neuroinflammation involving [cGAS-STING](/mechanisms/cgas-sting-neurodegeneration)

• Targeting upstream STING-CASM could prevent LRRK2 activation
• May be more effective than direct LRRK2 kinase inhibitors
• Could benefit both LRRK2 mutation carriers and sporadic patients

Crohn's Disease

The pathway also explains [LRRK2](/genes/lrrk2) activation in [Crohn's disease](/diseases/crohns-disease)[@qiu2024]:

• LRRK2 mutations increase Crohn's disease risk
• Gut inflammation activates STING
• Lysosomal damage in intestinal epithelial cells
• Potential for shared therapeutic approaches

Interaction with Other PD Mechanisms

Synucleinopathy

The pathway intersects with [alpha-synuclein](/proteins/alpha-synuclein) pathology:

• α-Synuclein aggregation can cause lysosomal dysfunction
• May trigger CASM and secondary LRRK2 activation
• Creates feed-forward loop: LRRK2 → autophagy dysfunction → α-synuclein accumulation

Mitochondrial Quality Control

[PINK1](/genes/pink1)-[PARK2](/genes/parkin) mitophagy pathway intersects with CASM:

• Mitophagy involves ATG8 family proteins
• Mitochondrial damage triggers [cGAS-STING](/mechanisms/cgas-sting-neurodegeneration)
• Potential convergence on LRRK2 activation

Neuroinflammation

The pathway is central to chronic neuroinflammation in [PD](/diseases/parkinsons-disease):

• STING activation leads to type I interferon responses
• Creates pro-inflammatory milieu
• May explain IFN signature observed in PD brains

Therapeutic Implications

Targeting STING-CASM-LRRK2

Multiple therapeutic strategies emerge from this pathway:

Direct STING inhibitors:

• H-151: Covalent STING antagonist
• C-176, C-178: STING inhibitors
• Would prevent CASM and subsequent LRRK2 activation

• Targeting ATG16L1
• ATG7 inhibition (Salip)
• ATG4B inhibition (SopF)

• Blocking LIR motif interactions
• Small molecule disruptors

• Addresses upstream activation
• May be beneficial for sporadic PD
• Broader therapeutic applicability

Biomarker Development

Pathway activation biomarkers could aid patient selection:

• Phospho-LRRK2 in CSF or blood
• GABARAP lipidation markers
• STING activation signatures
• Interferon-stimulated genes

Cross-Links to Related Mechanisms

• [cGAS-STING Pathway in Neurodegeneration](/mechanisms/cgas-sting-neurodegeneration)
• [LRRK2 Pathway in Parkinson's Disease](/mechanisms/lrrk2-pathway-parkinsons)
• [Autophagy-Lysosome Pathway](/mechanisms/autophagy-lysosome-pathway)
• [Neuroinflammation in Neurodegeneration](/mechanisms/neuroinflammation)
• [Parkinson's Disease Mechanisms](/mechanisms/parkinsons-disease-mechanisms)
• [GBA Lysosomal Function in Parkinson's](/mechanisms/gba-lysosomal-function-parkinsons)
• [Mitochondrial Dysfunction in Neurodegeneration](/mechanisms/mitochondrial-dysfunction)
• [Gut-Brain Axis in Neurodegeneration](/mechanisms/gut-brain-axis-neurodegeneration)

Key Proteins and Genes

| Protein/Gene | Function | Disease Link |
|--------------|----------|--------------|
| STING (TMEM173) | Innate immune sensor | Triggers CASM |
| LRRK2 | Leucine-rich repeat kinase | Kinase activation in PD |
| GABARAP | ATG8 family protein | Recruits LRRK2 |
| ATG16L1 | Autophagy protein | Essential for CASM |
| ATG7 | E1-like enzyme | ATG8 lipidation |
| ATG5 | Autophagy protein | ATG8 lipidation |
| cGAS | DNA sensor | STING activation |
| TBK1 | Kinase | Traditional STING pathway |

Summary

The STING-CASM-GABARAP-LRRK2 pathway represents a paradigm-shifting mechanism that integrates innate immune activation with LRRK2 kinase dysregulation in [Parkinson's disease](/diseases/parkinsons-disease). This pathway explains how diverse cellular stressors—including lysosomal damage, mitochondrial dysfunction, and microbial infection—converge to activate LRRK2 through a GABARAP-dependent mechanism.

The discovery of this pathway has important therapeutic implications:

Future research should focus on:

• Validating pathway activation in human PD brain tissue
• Developing brain-penetrant STING inhibitors
• Identifying biomarker signatures of pathway activation
• Testing therapeutic efficacy in preclinical models

References